What to Test in Parkinson Disease Prevention Trials?: Repurposed, Low-Risk, and Gene-Targeted Drugs

Despite the sound epidemiologic and basic science rationales underpinning numerous “disease modification” trials in manifest Parkinson disease (PD), none has convincingly demonstrated that a treatment slows progression. Rapidly expanding knowledge of the genetic determinants and prodromal features o...

Descripción completa

Detalles Bibliográficos
Autores principales: Crotty, Grace F., Schwarzschild, Michael A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
What Interventions to Test First
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10519134/
https://www.ncbi.nlm.nih.gov/pubmed/35970592
http://dx.doi.org/10.1212/WNL.0000000000200238

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10519134/
https://www.ncbi.nlm.nih.gov/pubmed/35970592
http://dx.doi.org/10.1212/WNL.0000000000200238

Ejemplares similares